Herpes zoster is a clustered blistering skin disease caused by the reactivation of the varicella-zoster virus latent in the ganglia, often accompanied by severe sequelae and complications, significantly reducing patients' quality of life and imposing psychological burdens. Vaccination is the most effective and economical option for preventing herpes zoster. At present, the herpes zoster recombinant protein vaccine is still the mainstream choice for current vaccination. With the increasing in the incidence of herpes zoster, domestic and foreign biological products companies have actively developed messenger RNA (mRNA) and various types of herpes zoster vaccines, effectively filling the gap in related fields in our country. This article systematically reviews the clinical manifestations and epidemiological characteristics of herpes zoster, and analyzes the research progress of currently marketed and pipeline herpes zoster vaccines, including live attenuated herpes zoster vaccine, recombinant protein herpes zoster vaccine, mRNA herpes zoster vaccine, adenovirus vector herpes zoster vaccine and virus-like particles herpes zoster vaccine, to provide reference for research and application in this field.

1.Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect?[J]. Clin Exp Vaccine Res, 2021, 10(2): 198-201. DOI: 10.7774/cevr.2021.10.2.198.

2.Liu H, Cui L, Zhang S, et al. Research progress on varicella-zoster virus vaccines[J]. Vaccines (Basel), 2025, 13(7): 730. DOI: 10.3390/vaccines13070730.

3.胡帅鹏, 张静静, 王朋超, 等. 带状疱疹疫苗研究进展[J]. 中国病毒病杂志, 2022, 12(5): 390-395. [Hu SP, Zhang JJ, Wang PC, et al. Research progress of herpes zoster vaccine[J]. Chinese Journal of Viral Diseases, 2022, 12(5): 390-395.] DOI: 10.16505/j.2095-0136.2022.0076.

4.Jin H, Ji Y, An J, et al. Engineering Escherichia coli for constitutive production of monophosphoryl lipid A vaccine adjuvant[J]. Biotechnol Bioeng, 2024, 121(3): 1144-1162. DOI: 10.1002/bit.28638.

5.陈静, 张强春, 张长国, 等. 普瑞巴林治疗疱疹后神经痛31例[J]. 药物流行病学杂志, 2013, 22(3): 121-122, 138.[Chen J, Zhang QC, Zhang CG, et al. Pregabalin in the treatment of postherpetic neuralgia in 31 cases[J]. Chinese Journal of Pharmacoepidemiology, 2013, 22(3): 121-122, 138.] DOI: 10.19960/j.cnki.issn1005-0698.2013.03.005.

6.张月, 毛子安. 带状疱疹疫苗的研究现状及临床评价[J]. 微生物学免疫学进展, 2025, 53(5): 88-94. [Zhang Y, Mao ZA. Research status and clinical evaluation of herpes zoster vaccine[J]. Microbiology and Immunology Exhibition, 2025, 53(5): 88-94.] DOI: 10.13309/j.cnki.pmi.2025.05.013.

7.Rouse BT, Schmid DS. Fraternal twins: the enigmatic role of the immune system in alphaherpesvirus pathogenesis and latency and its impacts on vaccine efficacy[J]. Viruses, 2022, 14(5): 862. DOI: 10.3390/v14050862.

8.张雪. 18岁及以上人群带状疱疹发病时间趋势及发病影响因素研究[D]. 杭州: 浙江中医药大学, 2024. DOI: 10.27465/d.cnki.gzzyc.2024.000070.

9.Gao C, Gao S, Zhao R, et al. Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome[J]. Sci Rep, 2024, 14(1): 19151. DOI: 10.1038/s41598-024-69819-0.

10.熊梅, 骆志成. 带状疱疹流行病学研究进展[J]. 实用临床医药杂志, 2022, 26(7): 144-148. [Xiong M, Luo ZC. Research progress on epidemiology of herpes zoster[J]. Journal of Practical Clinical Medicine, 2022, 26(7): 144-148.] DOI: 10.7619/jcmp.20214502.

11.Pan CX, Lee MS, Nambudiri VE. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review[J]. Ther Adv Vaccines Immunother, 2022, 10: 25151355221084535. DOI: 10.1177/25151355221084535.

12.Schmader K. Herpes zoster[J]. Ann Intern Med, 2018, 169(3): ITC19-ITC31. DOI: 10.7326/AITC201808070.

13.李娟, 吴疆. 带状疱疹的流行病学和疫苗免疫策略[J]. 慢性病学杂志, 2021, 22(8): 1145-1151. [Li J, Wu J. Epidemiology and vaccine immunization strategies of herpes zoster[J]. Journal of Chronic Diseases, 2021, 22(8): 1145-1151.] DOI: 10.16440/J.CNKI.1674-8166.2021.08.01.

14.Bloch KC, Johnson JG. Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster[J]. J Infect Dis, 2012, 205(9): 1331-1333. DOI: 10.1093/infdis/jis214.

15.Tommasi C, Drousioti A, Breuer J. The live attenuated varicella-zoster virus vaccine vOka: Molecular and cellular biology of its skin attenuation[J]. Hum Vaccin Immunother, 2025, 21(1): 2482286. DOI: 10.1080/21645515.2025.2482286.

16.Parikh R, Widenmaier R, Lecrenier N. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations[J]. Expert Rev Vaccines, 2021, 20(9): 1065-1075. DOI: 10.1080/14760584.2021.1956906.

17.Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines[J]. J Infect Dis, 2021, 224(12 Suppl 2): S429-S442. DOI: 10.1093/infdis/jiab387.

18.Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis[J]. Lancet Infect Dis, 2019, 19: 988-1000. DOI: 10.1016/S1473-3099(19)30163-X.

19.Litt J, Cunningham AL, Arnalich-Montiel F, et al. Herpes zoster ophthalmicus: presentation, complications, treatment, and prevention[J]. Infect Dis Ther, 2024, 13(7): 1439-1459. DOI: 10.1007/s40121-024-00990-7.

20.李娟, 李靖欣, 金鹏飞, 等. 带状疱疹疫苗临床研究进展 [J]. 中华疾病控制杂志, 2019, 23(11): 1409-1414. [Li J, Li JX, Jin PF, et al. Progress in research of clinical trials of herpes zoster vaccines[J]. Chinese Journal of Disease Control and Prevention, 2019, 23(11): 1409-1414.] DOI: 10.16462/j.cnki.zhjbkz.2019.11.022.

21.FDA. Shingrix (zoster vaccine recombinant, adjuvanted), suspension for intramuscular injection) package insert[EB/OL]. (2019-06-06) [2025-07-01]. https://www.fda.gov/media/108597/download.

22.Yaegashi M, Matsui H, Yoshida A, et al. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan[J]. Vaccine, 2024, 42(3): 464-470. DOI: 10.1016/j.vaccine.2023.12.082.

23.Alexandra Echeverria Proano D, Zhu F, Sun X, et al. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years:  a randomized, placebo-controlled trial[J]. Hum Vaccin Immunother, 2024, 20(1): 2351584. DOI: 10.1080/21645515.2024.2351584.

24.Pan HX, Qiu LX, Liang Q, et al. Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial[J]. Lancet Infect Dis, 2024, 24(8): 922-934. DOI: 10.1016/S1473-3099(24)00159-2.

25.Boutry C, Hastie A, Diez-Domingo J, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70[J]. Clin Infect Dis, 2022, 74(8): 1459-1467. DOI: 10.1093/cid/ciab629.

26.Choi WS, Choi JH, Jung DS, et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax (R) in healthy adults aged 50 years and older[J]. Vaccine, 2019, 37(27): 3605-3610. DOI: 10.1016/j.vaccine.2019.04.046.

27.Newswire P. SK bioscience's zoster vaccine receives biologics license application approval in Malaysia[EB/OL]. (2023-01-09) [2025-07-01]. https://en.prnasia.com/releases/global/sk-bioscience-s-zoster-vaccine-receives-biologics-license-application-approvalin-malaysia-389846.shtml.

28.BCHT. Live attenuated herpes zoster vaccine: Canvar®[EB/OL]. (2023-04-13) [2025-07-01]. http://www.bchtpharm.com/Home/Article/detail/id/905.html.

29.RxList. Zostavax[DB/OL]. (2024-09-26) [2025-07-01]. https://www.rxlist.com/zostavax-drug.htm#side_effects.

30.段立津, 高辉, 毛倩, 等. 水痘带状疱疹疫苗研发进展[J]. 中国预防医学杂志, 2023, 24(11): 1258-1264. DOI: 10.16506/j.1009-6639.2023.11.021.

31.Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(3): 103-108. DOI: 10.15585/mmwr.mm6703a5.

32.Hastie A, Catteau G, Enemuo A, et al. Immunogenicity of the adjuvanted recombinant zoster vaccine: persistenceand anamnestic response to additional doses administered 10 years after primary vaccination[J]. J Infect Dis, 2021, 224(12): 2025-2034. DOI: 10.1093/infdis/jiaa300.

33.Miller ER, Lewis P, Shimabukuro TT, et al. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015[J]. Hum Vaccin Immunother, 2018, 14(8): 1963-1969. DOI: 10.1080/21645515.2018.1456598.

34.Lang PO, Aspinall R. Vaccination for quality of life: herpes-zoster vaccines[J]. Aging Clin Exp Res, 2021, 33(4): 1113-1122. DOI: 10.1007/s40520-019-01374-5.

35.Tang E, Ray I, Arnold BF, et al. Recombinant zoster vaccine and the risk of dementia[J]. Vaccine, 2025, 46: 126673. DOI: 10.1016/j.vaccine.2024.126673.

36.Mollo A, Peri M, Lodi L, et al. Considering recombinant herpes zoster vaccine for fragile pediatric patients: a new opportunity[J]. Vaccine, 2025, 53: 127072. DOI: 10.1016/j.vaccine.2025.127072.

37.Rayens E, Sy LS, Qian L, et al. Effectiveness and safety of the recombinant zoster vaccine in individuals ≥ 50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study[J]. Ann Rheum Dis, 2025, 84(6): 960-969. DOI: 10.1016/j.ard.2025.01.045.

38.Stempniewicz N, Davenport E, Wang J, et al. Herpes zoster vaccination: primary care provider knowledge, attitudes, and practices[J]. Hum Vaccin Immunother. 2025, 21(1): 2488093. DOI: 10.1080/21645515.2025.2488093.

39.Huang L, Zhao T, Zhao W, et al. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques[J]. Emerg Microbes Infect, 2024, 13(1): 2309985. DOI: 10.1080/22221751.2024.2309985.

40.Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation[J]. Nat Rev Drug Discov, 2021, 20: 817-838. DOI: 10.1038/s41573-021-00283-5.

41.Moderna. Moderna advances multiple vaccine programs to late-stage clinical trials[EB/OL]. (2024-03-27) [2025-07-01]. https://news.modernatx.com/news/news-details/2024/Moderna-Advances-Multiple-Vaccine-Programs-to-Late-Stage-Clinical-Trials/default.aspx.

42.Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure[J]. Clin Infect Dis, 2021, 73(6): 941-948. DOI: 10.1093/cid/ciab125.

43.丁惠如. 表达水痘—带状疱疹病毒gE蛋白的重组腺病毒载体疫苗不同免疫途径效果研究[D]. 北京: 北京交通大学, 2023. DOI: 10.26944/d.cnki.gbfju.2023.001019.

44.Dynavax. Advancing a broad pipeline of vaccines to prevent infectious diseases[EB/OL]. (2022-10-01) [2025-07-01]. https://www.dynavax.com/pipeline/#trials.

45.Pfizer. Pfizer and BioNTech initiate phase 1/2 study of first mRNA-based shingles vaccine program[EB/OL]. (2023-02-10) [2025-07-01]. https: //www.pfizer.com/news/announcements/pfizer-and-biontech-initiate-phase-12-study-first-mrnabased-shingles-vaccine..

46.Innorna. Innorna shingles mRNA vaccine IN001 has been approved for clinical trials in China[EB/OL]. (2024-07-23) [2025-07-01]. https://www.innorna.com/cn/news/314.html.

47.Ulaszewska M, Merelie S, Sebastian S, et al. Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster[J]. Hum Vaccin Immunother, 2023, 19(1): 2175558. DOI: 10.1080/21645515.2023.2175558.

48.张雅丽, 苏文哲, 马超锋, 等. 抗水痘-带状疱疹病毒药物的耐药研究进展[J]. 中华预防医学杂志, 2023, 57(2): 259-267. [Zhang YL, Su WZ, Ma CF, et al. Rsearch progress on drug resistance of anti-varicella-zoster virus drugs[J]. Chinese Journal of Preventive Medicine, 2023, 57(2): 259-267.] DOI: 10.3760/cma.j.cn112150-20220825-00839.

49.SINOVAC. SINOVAC freeze-dried herpes zoster virus mRNA vaccine approved for clinical use[EB/OL]. (2024-12-26) [2025-07-01]. https://www.sinovac.com/zh-cn/news/id-3385.

50.Shah R, Amador C, Tormanen K, et al. Systemic diseases and the cornea[J]. Exp Eye Res, 2021, 204: 108455. DOI: 10.1016/j.exer.2021.108455.

51.Walewangko OC, Purnomo JS, Jo PA, et al. Prophylactic vaccination strategies for adult patients with diabetes: a narrative review of safety profiles and clinical effectiveness[J]. Clin Exp Vaccine Res, 2025, 14(2): 101-115. DOI: 10.7774/cevr.2025.14.e11.

52.García A, Vallejo-Aparicio LA, Cambronero Martinez R. The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain[J]. Hum Vaccin Immunother, 2024, 20(1): 2366353. DOI: 10.1080/21645515.2024.2366353.

53.Marra Y, Lalji F. Prevention of herpes zoster: a focus on the effectiveness and safety of herpes zoster vaccines[J]. Viruses, 2022, 14(12): 2667. DOI: 10.3390/v14122667.

54.Wollina U, Chiriac A, Kocic H, et al. Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination-a narrative review[J]. Wien Med Wochenschr, 2022, 172(3-4): 63-69. DOI: 10.1007/s10354-021-00876-0.

55.高睿迪, 王伟. 水痘-带状疱疹疫苗的应用及研究进展 [J]. 临床皮肤科杂志, 2021, 50(1): 62-64. [Gao RD, Wang W. Application and research progress of varicella-zoster vaccine[J]. Journal of Clinical Dermatology, 2021, 50(1): 62-64.] DOI: 10.16761/j.cnki.1000-4963.2021.01.020.

56.Petherbridge L, Davis C, Robinson A, et al. Pre-clinical development of an adenovirus vector based RSV and shingles vaccine candidate[J]. Vaccines (Basel), 2023, 11(11): 1679. DOI: 10.3390/vaccines11111679.

57.Nie J, Sun Y, Feng K, et al. The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process[J]. Vaccine, 2022, 40(13): 2036-2043. DOI: 10.1016/j.vaccine.2022.02.024.

58.Choi WS, Choi JH, Jung DS, et al. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older[J]. Vaccine, 2019, 37(27): 3605-3610. DOI: 10.1016/j.vaccine.2019.04.046.

59.CanSinoBio. CanSinoBio recombinant herpes zoster vaccine launches phase I clinical trial in Canada and completes first subject enrollment[EB/OL]. (2023-11-09) [2025-07-01]. https://www.cansinotech.com.cn/detail-4188.

60.Sun Y, Huang L, Nie J, et al. Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production[J]. AMB Express, 2022, 12(1): 58. DOI: 10.1186/s13568-022-01398-7.

61.Lape M, Schnell D, Parameswaran S, et al. A survey of pathogenic involvement in non-communicable human diseases[J]. Commun Med (Lond), 2025, 5(1): 242. DOI: 10.1038/s43856-025-00956-x.

62.Tommasi C, Drousioti A, Breuer J. The live attenuated varicella-zoster virus vaccine vOka: molecular and cellular biology of its skin attenuation[J]. Hum Vaccin Immunother, 2025, 21(1): 2482286. DOI: 10.1080/21645515.2025.2482286.

63.Lee C, Kim M, Chun J, et al. Baculovirus vector-based varicella-zoster virus vaccine as a promising alternative with enhanced safety and therapeutic functions[J]. Vaccines, 2024, 12: 333. DOI: 10.3390/vaccines12030333.

64.Munoz-Moreno R, Allaj V, Gadee E, et al. A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses[J]. NPJ Vaccines, 2025, 10(1): 49. DOI: 10.1038/s41541-025-01093-1.

65.Jang SO, Lee JH, Chung YJ, et al. Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response[J]. Virology, 2024, 600: 110243. DOI: 10.1016/j.virol.2024.110243.

66.Santovito LS, Pinna G. A case of reactivation of varicella-zoster virus after BNT162b2 vaccine second dose?[J]. Inflamm Res, 2021, 70: 935-937. DOI: 10.1007/s00011-021-01491-w.

67.Perciani CT, Sekhon M, Hundal S, et al. Live attenuated zoster vaccine boosts varicella zoster virus (VZV)-specific humoral responses systemically and at the cervicovaginal mucosa of Kenyan VZV-seropositive women[J]. J Infect Dis, 2018, 218: 1210-1218. DOI: 10.1093/infdis/jiy320.

68.Warrington R, Ismail S. Summary of the NACI update on herpes zoster vaccines[J]. Can Commun Dis Rep, 2018, 44(9): 220-225. DOI: 10.14745/ccdr.v44i09a06.